サンプル依頼リスト カート
  • English
  • Korean
表紙：性交疼痛治療薬の世界市場：2023年～2030年
市場調査レポート
商品コード
1382547

性交疼痛治療薬の世界市場：2023年～2030年

Global Dyspareunia Drugs Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 187 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
性交疼痛治療薬の世界市場：2023年～2030年
出版日: 2023年11月17日
発行: DataM Intelligence
ページ情報: 英文 187 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

性交困難症は、性交前、性交中、性交後に経験する性器の痛みによって定義されます。特定の病因を特定することは困難であるため、この病態を性的障害または疼痛障害に分類できるかどうかは議論の余地があります。性交疼痛障害は、身体的・精神的健康や生活の質に重大な影響を及ぼす可能性があります。この活動では、性交困難症の評価と管理について説明し、この病態の患者の管理における専門職間チームの役割を強調します。

性交困難症の病因には、構造的、炎症性、感染性、腫瘍性、外傷性、ホルモン性および心理社会的条件が含まれます。解剖学的原因には、骨盤底筋機能障害、子宮後屈、子宮遺残、骨盤臓器脱などがあります。潤滑不足は生殖期に最も多く、ホルモンおよび性的興奮障害に起因します。

市場力学：促進要因と阻害要因

疾患に対する認識の高まり

病気に対する意識の高まりは、予測期間中の市場を後押しする重要な主要要因の一つです。薬剤師は、性交障害に対するアンメットニーズに対応し、中等度から重度の性交障害患者に対するイントラローザに関する具体的な情報など、性交障害に対する利用可能な治療選択肢について閉経後女性のカウンセリングを行う上で、独自の立場にあります。閉経後の集団では、しばしばVVAに関する会話を始めることができないことを考えると、このデリケートな状態について議論する潜在的な障壁について理解している薬剤師は、適切な場合に患者と会話を始めるためのより良い能力を備えているかもしれないです。

例えば、2023年8月、外陰膣萎縮症（VVA）に対するラソフォキシフェンの新規製剤を開発している非公開の女性健康企業であるAzure Biotech, Inc.は、何百万人もの女性に影響を及ぼしているこの十分な治療を受けていない更年期の健康状態にある女性を支援するための教育キャンペーンを開始しました。

米国国立衛生研究所によると、女性は人生の30～40％を更年期に費やすが、更年期障害、症状、病態、治療に関する話題は、仲間、パートナー、医師、さらにはメディアの間でさえ、一般的にオープンに議論されることはないです。Azureのキャンペーンの目的は、この対話の場を開き、一般の人々を教育することです。Azureは、whatsVVA.comというウェブサイトを作成し、この十分なサービスを受けていないコミュニティに貴重なリソースを提供しています。

市場力学：抑制

性交疼痛症は通常治療可能な疾患であり、合併症もあります。疾患の悪性でない性質にかかわらず、苦痛を伴う後遺症を避けるためには、タイムリーな管理と介入が極めて重要です。患者が迅速かつ適切な治療を受けなければ、性的関心が失われ、人間関係に問題が生じる可能性があります。また、重大な苦痛やパートナー間の葛藤をもたらします。性交困難症は、性欲や興奮の減退だけでなく、患者の精神的・身体的健康、身体イメージ、人間関係、妊娠への努力に悪影響を及ぼす可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 疾患に対する認識の高まり
      • 新薬の上市
  • 抑制要因
      • 薬剤に伴う合併症
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • パイプライン分析
  • アンメットニーズ
  • DMI意見

第6章 COVID-19分析

第7章 疾患タイプ別

  • 表在性性交疼痛
  • 深在性性膣障害

第8章 薬剤クラス別

  • エストロゲン
  • 選択的エストロゲン受容体モジュレーター
  • その他の膣剤
  • その他

第9章 投与経路別

  • 経口剤
  • 膣挿入剤

第10章 流通チャネル別

  • 病院薬局
  • オンライン薬局
  • 小売薬局

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Pfizer
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Therapeutics MD
  • Myovant
  • Novo Nordisk
  • Duchesnay USA Inc
  • Maynepharma
  • Manus Aktteva Biopharma LLP
  • Lupin Pharma Canada
  • Verity Pharma
  • Teva Pharmaceuticals

第14章 付録

目次
Product Code: PH7472

Overview

Dyspareunia is defined by genital pain that can be experienced before, during, or after intercourse. It is debatable whether this condition can be classified as a sexual disorder or pain disorder as identifying a specific etiology can prove challenging. Dyspareumia can have a significant effect on physical and mental health, as well as quality of life. This activity illustrates the evaluation and management of dyspareunia and highlights the role of the interprofessional team in managing patients with this condition.

The etiology of dyspareunia encompasses structural, inflammatory, infectious, neoplastic, traumatic, hormonal, and psychosocial conditions. Anatomic causes include pelvis floor muscle dysfunction, uterine retroversion, hymenal remnants, and pelvic organ prolapse. Lack of lubrication is most common in reproductive years and is attributable to hormonal as well as sexual arousal disorders.

Market Dynamics: Drivers and Restraints

Increasing awareness about the disease

Increasing awareness about the disease is one of the significant key factors that help the market during the forecast period. Pharmacists are uniquely positioned to address the unmet need for dyspareunia awareness and to counsel postmenopausal women on available treatment options for dyspareunia, including specific information regarding intrarosa for those with moderate to severe dyspareunia. Given that there often is a failure to initiate conversations around VVA in the postmenopausal population, pharmacists with an understanding of potential barriers to discussing this sensitive condition may be better equipped to initiate conversations with patients when appropriate.

For instance, in August 2023, Azure Biotech, Inc., a privately held women's health company that is developing novel formulations of lasofoxifene for vulvovaginal atrophy (VVA), launched an educational campaign to support women with this underserved menopausal health condition affecting millions of women.

According to the National Institutes of Health, women spend 30-40% of their lives in menopause, yet the topic of menopause, symptoms, conditions, and treatments is typically not openly discussed among peers, partners, doctors, and even in the media. The objective of Azure's campaign is to open this dialog and educate the public. Azure has created a website, whatsVVA.com providing valuable resources to this underserved community.

Market Dynamics: Restraint

Dyspareunia is usually a treatable disease and has some complications. Regardless of the non-malignant nature of the disease, timely management and intervention are crucial to obviate distressing sequelae. If the patients do not seek prompt, appropriate medical care, it can result in loss of sexual interest and problems with relationships. It also results in significant distress and conflicts among the partners. Dyspareunia can lead to negative impacts on a patient's mental and physical health, body image, relationships, and conceiving efforts, as well as decreased libido and arousal.

Segment Analysis

The global dyspareunia drugs market is segmented based on disease type, drug type, route of administration, distribution channel and region.

The estrogen segment from the drug class segment accounted for approximately 41.7% of the dyspareunia drugs market share

The estrogen segment from the drug class segment accounted for approximately 41.7% and it is expected to be dominated during the forecast period. Estrogen is a steroid hormone associated with the female reproductive organs and is responsible for developing female sexual characteristics. Estrogen or estradiol is the most common form of estrogen hormone for FDA-approved treatment as hormone replacement therapy (HRT) in managing symptoms associated with menopause.

For instance, in February 2022, Duchesnay Inc., a pharmaceutical company specializing in women's health and part of the Duchesnay pharmaceutical group based in Blainville, Quebec, stated that the first treatment launched by its new ownership and management team to help postmenopausal women across Canada who are suffering from vaginal dryness and painful intercourse. Osphena (ospemifene tablets), a Selective Estrogen Receptor Modulator (SERM) now available across Canada, has been approved by Health Canada as a once-daily prescription treatment for this indication.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the awareness program launches, collaborations and agreements with key players, advanced medical technology, research and development, public awareness campaigns and others that will drive this region to be highest market share during the forecast period.

For instance, in June 2020, Duchesnay USA, a pharmaceutical company that specializes in women's health, is proud to announce the launch of a new video titled Straight Talk: Sex and the Menopausal Woman. Produced in collaboration with FabOverFifty, a leading online platform for women over 50, this video is the latest in a series of videos offered by Duchesnay USA to educate women about moderate to severe vaginal dryness and dyspareunia due to menopause.

Moreover, in May 2020, Millicent Pharma Limited, a global pharmaceutical company formed by the Millicent Pharma management team and The Carlyle Group, stated a definitive agreement to acquire the U.S. commercial rights to Intrarosa (prasterone) from AMAG Pharmaceuticals, Inc. a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs. Intrarosa is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.

COVID-19 Impact Analysis

COVID-19 had a substantial impact on the dyspareunia drugs market where the impact of the COVID-19 pandemic on women's sexual life and frequency of intercourse, as well as stress and anxiety levels. The study also found that deteriorating partner relationships and increased stress and anxiety levels were linked to the pandemic. Doctors should provide anamnesis suggest psychotherapy if applicable, and consider telemedicine for facilitating contact with sexologists during this challenging time.

Market Segmentation

By Disease Type

  • Superficial Dyspareunia
  • Deep Dyspareunia

By Drug Class

  • Estrogens
  • Selective Estrogen Receptor Modulators
  • Miscellaneous Vaginal Agents
  • Others

By Route of Administration

  • Oral
  • Vaginal Inserts

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the market include: Pfizer, Therapeutics MD, Myovant, Novo Nordisk, Duchesnay USA Inc, Maynepharma, Manus Aktteva Biopharma LLP, Lupin Pharma Canada, Verity Pharma, Teva Pharmaceuticals and among others.

Key Developments

  • In January 2023, Lupine Pharma Canada stated the launch of a novel treatment for postmenopausal vulvovaginal atrophy called Intrarosa@ (prasterone vaginal ovules). Dyspareunia (painful intercourse), vaginal dryness, irritation, and itching are symptoms of menopause that are managed with this treatment. Additionally, Intrarosa@, which has a unique mode of action, responds quickly and has a safe profile, as it targets both estrogen and androgen deficiencies.
  • On February 14, 2022, Duchesnay, Inc., a pharmaceutical company specializing in women's health and part of the Duchesnay Pharmaceutical Group based in Blainville, Quebec, announced the first treatment launched to help postmenopausal women suffering from vaginal dryness and painful intercourse across Canada. Osphena (ospemifene tablets), a Selective Estrogen Receptor Modulator (SERM) now available across Canada, has been approved by Health Canada as a once-daily prescription treatment for this indication.

Why Purchase the Report?

  • To visualize the global dyspareunia drugs market segmentation based on disease type, drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of dyspareunia drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global dyspareunia drugs market report would provide approximately 69 tables, 58 figures and 187 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Disease Type
  • 3.2. Snippet by Drug Class
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Market Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing awareness about the disease
      • 4.1.1.2. Novel drug launches
  • 4.2. Restraints
      • 4.2.1.1. Complications associated with the drugs
    • 4.2.2. Opportunity
    • 4.2.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Unmet Needs
  • 5.7. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type
  • 7.2. Superficial Dyspareunia *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Deep Dyspareunia

8. By Drug Class

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 8.1.2. Market Attractiveness Index, By Drug Class
  • 8.2. Estrogens *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Selective Estrogen Receptor Modulators
  • 8.4. Miscellaneous Vaginal Agents
  • 8.5. Others

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Oral*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Vaginal Inserts

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Pfizer *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Therapeutics MD
  • 13.3. Myovant
  • 13.4. Novo Nordisk
  • 13.5. Duchesnay USA Inc
  • 13.6. Maynepharma
  • 13.7. Manus Aktteva Biopharma LLP
  • 13.8. Lupin Pharma Canada
  • 13.9. Verity Pharma
  • 13.10. Teva Pharmaceuticals

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us